1

2022
Strontium
ranelate
In the treatment of osteoarthritis
5
3

0 1

Strontium
ranelate
2 Phrmacokinitics
Safety

Clinical trials

Clinical efficacy

Recommendations
Chemistry
C o n t e n t s
8 Safety&AE

Well toler ated

Diarrhea

Cacardiovadcular
event
 Pathogenesis 4

Memories flashed across my mind as I came a

across the first photo of myself as a little baby.
Nostalgia took me to the depths of past.

Memories flashed across my mind as I came a

across the first photo of myself as a little baby.
Nostalgia took me to the depths of past.
7 Pharmacokinetics

A M

Absor ption Metabolism

D o s e C Y P 4 5 0 ? ?
d e p e n d e n t
F o o d ? ?
D E

Dist ribution Excretion

B o n e K i d n e y

t i s s u e ? ? a n d G I T

B l a s m a s e c r e t i o n

p r o t e i n
b i n d i n g ? ?
9 Recommendations

SrRan is not approved by the FDA for use in the US,

but the EMA has endorsed its use for a long time. However, there is a recent
recommendation for discontinuation
of the drug marketing in Europe by the manufacturer.

EMA recommended in 2014 that strontium ranelate remain available for patients
with osteoporosis with restrictions relative to patients with existing heart disease

Caution
to patients
with osteoarthritis have uncontrolled hypertension, history of ischemic heart
 6 Clinical effect

Osteoporosis

R e d u c e s
v e r t e b r a l
a n d
n o n v e r t e b r a
l f r a c t u r e s
i n
p o s t m e n o p a u
s a l w o m e n
w i t h
O steoart hritis
o s t e o p o r o s i s

D M O A D , 1
a n d 2
g / d a y
s t r u c t u r a
l
m o d i f i e r
10

THANK YOU
2022 This is prepared by: Hadeel Braika